Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 100
interventional 96
Observational 3
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 39
Drug|Other 19
Biological|Drug 6
Biological|Drug|Other 4
Drug|Procedure|Radiation 4
Biological 3
Biological|Drug|Other|Procedure 3
Drug|Other|Procedure|Radiation 3
Drug|Procedure 3
Biological|Drug|Other|Procedure|Radiation 2
Biological|Other 2
Drug|Other|Procedure 2
Other|Procedure 2
Biological|Drug|Procedure|Radiation 1
Dietary Supplement|Drug 1
Drug|Genetic|Other 1
Drug|placebo|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 74
NA 4
France 2
United States|Canada 2
Belgium|Denmark|France|Germany|Italy|Netherlands|Spain|Sweden|United Kingdom 1
Brazil 1
Canada 1
Colombia|Venezuela 1
Italy 1
Poland 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Finland|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Norway|Peru|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Denmark|Finland|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Norway|Philippines|Singapore|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Canada 1
United States|Denmark|Germany 1
United States|France|Germany|Italy 1
United States|Germany 1
United States|Germany|Italy 1
United States|Italy 1

Sites per Study

Site_count Study_Count
1 67
2 6
3 4
4 2
5 2
8 1
9 3
10 2
11 1
15 1
25 1
26 2
29 1
38 1
60 1
62 1

Phase

Phase Study_Count
Phase 2 35
Phase 1 34
Phase 1/Phase 2 15
N/A 6
Phase 2/Phase 3 2
Phase 3 2
Phase 4 2

Number of Arms

Number_of_Arms Count_of_Studies
1 68
2 13
3 4
4 2
NA 9

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 5.00000 5.00000 25.00000 11 27 6.00 19.0
1st Qu. 6.50000 25.00000 35.75000 35 30 338.75 36.5
Median 14.00000 35.00000 47.50000 60 33 671.50 54.0
Mean 23.83333 41.78788 52.57143 81 33 671.50 54.0
3rd Qu. 23.00000 45.00000 58.50000 100 36 1004.25 71.5
Max. 80.00000 145.00000 132.00000 408 39 1337.00 89.0

Trial Group Type

group_type Group_Count
Experimental 105
NA 9
Active Comparator 6
Other 2
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 77
Parallel Assignment 15
NA 3
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 87
Supportive Care 8
Prevention 1

Observational Studies

Studies by Country

Country Study_Count
United States 2
Ireland|United Kingdom 1

Sites per Study

Site_count Study_Count
1 1
2 1
33 1

Enrollment Metrics

Measure Observational
Min 153.0000
1st Qu 226.5000
Median 300.0000
Mean 284.3333
3rd Qu 350.0000
Max 400.0000

Observation Model

observational_model Study_Count
Cohort 1
Other 1
NA 1

Time Perspective

time_perspective Study_Count
Prospective 2
NA 1

Registries

Studies by Country

Country Study_Count
Czechia|Germany|Russian Federation|Ukraine 1

Sites per Study

Site_count Study_Count
9 1

Enrollment Metrics

Measure Registries
Min 250
1st Qu 250
Median 250
Mean 250
3rd Qu 250
Max 250

Registry Model

observational_model Study_Count
Case-Only 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
1 Day 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03326921 HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03326921 Recruiting Fred Hutchinson Cancer Research Center 2023-12-16
NCT03263572 Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT03263572 Recruiting M.D. Anderson Cancer Center 2023-11-30
NCT03147612 Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT03147612 Recruiting M.D. Anderson Cancer Center 2024-02-08
NCT02782403 Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02782403 Active, not recruiting M.D. Anderson Cancer Center 2020-08-31
NCT02730312 PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02730312 Recruiting Xencor, Inc. 2020-08-31
NCT02311998 Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML https://ClinicalTrials.gov/show/NCT02311998 Recruiting M.D. Anderson Cancer Center 2021-04-01
NCT02530034 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02530034 Recruiting M.D. Anderson Cancer Center 2022-01-31
NCT02220985 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD https://ClinicalTrials.gov/show/NCT02220985 Active, not recruiting Fred Hutchinson Cancer Research Center 2025-04-01
NCT02115295 Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02115295 Recruiting M.D. Anderson Cancer Center 2021-05-19
NCT02091245 Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML https://ClinicalTrials.gov/show/NCT02091245 Active, not recruiting Dana-Farber Cancer Institute 2018-02-28
NCT01858740 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children https://ClinicalTrials.gov/show/NCT01858740 Active, not recruiting Fred Hutchinson Cancer Research Center 2022-01-30
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT01823198 Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies https://ClinicalTrials.gov/show/NCT01823198 Active, not recruiting M.D. Anderson Cancer Center 2020-06-30
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01498445 An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) https://ClinicalTrials.gov/show/NCT01498445 Active, not recruiting M.D. Anderson Cancer Center 2020-06-30
NCT01428635 Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy https://ClinicalTrials.gov/show/NCT01428635 Active, not recruiting M.D. Anderson Cancer Center 2020-01-31
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01424982 Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT01424982 Recruiting M.D. Anderson Cancer Center 2021-10-31
NCT01368523 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial https://ClinicalTrials.gov/show/NCT01368523 Completed Novartis 2010-01-31
NCT03878524 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial https://ClinicalTrials.gov/show/NCT03878524 Recruiting OHSU Knight Cancer Institute 2022-02-27
NCT04282187 Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT04282187 Recruiting University of Washington 2024-11-11
NCT04188405 Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT04188405 Recruiting M.D. Anderson Cancer Center 2024-09-01
NCT03934372 Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors https://ClinicalTrials.gov/show/NCT03934372 Recruiting Incyte Corporation 2021-10-31
NCT03895671 PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS https://ClinicalTrials.gov/show/NCT03895671 Recruiting Versailles Hospital 2023-12-01
NCT03842696 Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation https://ClinicalTrials.gov/show/NCT03842696 Recruiting University of Michigan Rogel Cancer Center 2024-02-29
NCT03630991 Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy https://ClinicalTrials.gov/show/NCT03630991 Active, not recruiting M.D. Anderson Cancer Center 2020-12-31
NCT03595917 ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML https://ClinicalTrials.gov/show/NCT03595917 Recruiting Dana-Farber Cancer Institute 2021-11-01
NCT03589729 Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers https://ClinicalTrials.gov/show/NCT03589729 Recruiting M.D. Anderson Cancer Center 2020-12-31
NCT03576547 Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT03576547 Recruiting M.D. Anderson Cancer Center 2022-01-31
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01231919 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT01231919 Completed National Cancer Institute (NCI) 2013-04-30
NCT01204164 Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT01204164 Completed Tragara Pharmaceuticals, Inc. 2016-03-31
NCT01126892 A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase https://ClinicalTrials.gov/show/NCT01126892 Completed Novartis 2011-04-30
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT01056614 Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies https://ClinicalTrials.gov/show/NCT01056614 Completed Fred Hutchinson Cancer Research Center 2005-08-31
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT00964873 A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00964873 Completed Synta Pharmaceuticals Corp. 2010-12-31
NCT00860574 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT00860574 Completed Fred Hutchinson Cancer Research Center 2013-02-28
NCT00816283 Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT00816283 Completed City of Hope Medical Center 2011-06-30
NCT01904136 Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT01904136 Active, not recruiting M.D. Anderson Cancer Center 2021-04-30
NCT00786812 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase https://ClinicalTrials.gov/show/NCT00786812 Completed Novartis 2012-01-31
NCT00763763 Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive https://ClinicalTrials.gov/show/NCT00763763 Completed Assistance Publique - Hôpitaux de Paris 2007-10-31
NCT00702403 Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML https://ClinicalTrials.gov/show/NCT00702403 Completed Fred Hutchinson Cancer Research Center 2013-12-31
NCT00636909 Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders https://ClinicalTrials.gov/show/NCT00636909 Completed Beth Israel Deaconess Medical Center 2006-03-31
NCT00540995 Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer https://ClinicalTrials.gov/show/NCT00540995 Active, not recruiting City of Hope Medical Center 2011-12-10
NCT00538109 An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase https://ClinicalTrials.gov/show/NCT00538109 Completed King Faisal Specialist Hospital & Research Center 2013-10-31
NCT00514969 Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase https://ClinicalTrials.gov/show/NCT00514969 Completed University of Bologna NA
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00459212 GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00459212 Completed National Cancer Institute (NCI) 2010-12-31
NCT00449761 Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis) https://ClinicalTrials.gov/show/NCT00449761 Completed Novartis 2008-08-31
NCT00426205 GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies https://ClinicalTrials.gov/show/NCT00426205 Completed Dana-Farber Cancer Institute 2007-09-30
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00390793 Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. https://ClinicalTrials.gov/show/NCT00390793 Active, not recruiting M.D. Anderson Cancer Center 2020-08-31
NCT00799461 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications https://ClinicalTrials.gov/show/NCT00799461 Completed Fred Hutchinson Cancer Research Center 2011-11-30
NCT00381550 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00381550 Completed National Cancer Institute (NCI) 2011-03-31
NCT00357305 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00357305 Completed National Cancer Institute (NCI) 2011-11-30
NCT00331513 Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes https://ClinicalTrials.gov/show/NCT00331513 Completed National Cancer Institute (NCI) 2010-01-31
NCT00316953 Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate https://ClinicalTrials.gov/show/NCT00316953 Completed National Cancer Institute (NCI) 2009-09-30
NCT00309907 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00309907 Completed Children’s Oncology Group 2011-09-30
NCT00301938 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes https://ClinicalTrials.gov/show/NCT00301938 Completed National Cancer Institute (NCI) 2012-05-31
NCT00278330 Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia https://ClinicalTrials.gov/show/NCT00278330 Completed National Cancer Institute (NCI) 2009-10-31
NCT00275080 Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00275080 Completed National Cancer Institute (NCI) 2009-11-30
NCT00258271 Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00258271 Completed University of Rochester 2006-10-31
NCT00217646 Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00217646 Completed National Cancer Institute (NCI) 2010-12-31
NCT00171158 An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis https://ClinicalTrials.gov/show/NCT00171158 Completed Novartis 2013-04-30
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00103701 BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT00103701 Completed Bristol-Myers Squibb 2006-03-31
NCT00101816 Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate https://ClinicalTrials.gov/show/NCT00101816 Completed Bristol-Myers Squibb 2006-08-31
NCT00098423 Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes https://ClinicalTrials.gov/show/NCT00098423 Completed National Cancer Institute (NCI) 2009-05-31
NCT00098826 SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes https://ClinicalTrials.gov/show/NCT00098826 Completed National Cancer Institute (NCI) 2008-05-31
NCT00095797 XK469R in Treating Patients With Refractory Hematologic Cancer https://ClinicalTrials.gov/show/NCT00095797 Completed National Cancer Institute (NCI) 2007-03-31
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00087204 Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00087204 Completed National Cancer Institute (NCI) 2007-01-31
NCT00084916 CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase https://ClinicalTrials.gov/show/NCT00084916 Completed National Cancer Institute (NCI) 2007-03-31
NCT00003997 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00003997 Completed National Cancer Institute (NCI) 2000-10-31
NCT00081874 RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00081874 Completed M.D. Anderson Cancer Center 2006-09-30
NCT00006475 STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis https://ClinicalTrials.gov/show/NCT00006475 Completed Novartis 2002-12-31
NCT00003735 Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00003735 Completed Children’s Oncology Group 2002-11-30
NCT00081133 Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT00081133 Completed Memorial Sloan Kettering Cancer Center 2005-02-28
NCT00077467 Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia https://ClinicalTrials.gov/show/NCT00077467 Completed National Cancer Institute (NCI) 2006-03-31
NCT00077181 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00077181 Completed National Cancer Institute (NCI) 2008-07-31
NCT00005064 PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00005064 Completed National Cancer Institute (NCI) 2002-10-31
NCT00006213 BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00006213 Completed National Cancer Institute (NCI) 2002-10-31
NCT00068718 Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant https://ClinicalTrials.gov/show/NCT00068718 Completed Fred Hutchinson Cancer Research Center 2013-04-30
NCT00067028 Clofarabine Combinations in Relapsed/Refractory AML, MDS and Myeloid Blast Phase CML https://ClinicalTrials.gov/show/NCT00067028 Completed M.D. Anderson Cancer Center 2013-06-30
NCT00054431 Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00054431 Completed National Cancer Institute (NCI) 2007-05-31
NCT00053963 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT00053963 Completed National Cancer Institute (NCI) 2006-02-28
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00015834 STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00015834 Completed National Cancer Institute (NCI) 2003-04-30
NCT00012376 Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer https://ClinicalTrials.gov/show/NCT00012376 Completed National Cancer Institute (NCI) 2010-01-31
NCT00042003 Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) https://ClinicalTrials.gov/show/NCT00042003 Completed Astex Pharmaceuticals, Inc. 2004-12-31
NCT00034684 Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) https://ClinicalTrials.gov/show/NCT00034684 Completed Merck Sharp & Dohme Corp. 2003-10-31
NCT00111683 MK0457 in Patients With Leukemia (0457-003) https://ClinicalTrials.gov/show/NCT00111683 Completed Merck Sharp & Dohme Corp. 2008-05-31
NCT00105001 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00105001 Completed Fred Hutchinson Cancer Research Center 2011-05-31
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00101595 Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT00101595 Completed Bristol-Myers Squibb 2007-12-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02455024 An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® https://ClinicalTrials.gov/show/NCT02455024 Recruiting Takeda 2020-09-30
NCT03647215 CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey https://ClinicalTrials.gov/show/NCT03647215 Recruiting Incyte Corporation 2020-06-30
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03869502 European CML Blast Crisis Register https://ClinicalTrials.gov/show/NCT03869502 Recruiting University of Jena 2024-06-30